PMPRB Summary of VCUs & Orders - 1995
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| Oct. 10, 1995 |
Betaseron |
Berlex Canada Inc. |
2.3 |
Yes - $91.43/vial |
$27,415 |
- |
|
| May 23, 1995 |
Hepatate II |
Amersham Canada Limited |
3.4 - 9.6 |
Yes - $8.92/vial |
$16,286 |
- |
|
| April 20, 1995 |
Beclomethasone |
Kenral Inc. |
6.2 - 7.2 |
No |
$72,054 |
$72,054 |
Expired 08/1993 |
| ORDER |
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.